Join Growin Stock Community!

華廣4737.TW Overview

TW StockBiotech. & Medical
(No presentation for 4737)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

華廣（4737）Overall Performance

華廣（4737）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

華廣（4737） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

華廣（4737）Key Information

華廣（4737）Profile

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

華廣（4737）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
20.83
PS Ratio (TTM)
2.22
PB Ratio
2.29
Price-to-FCF
70.38
METRIC
VALUE
vs. INDUSTRY
Gross Margin
33.52%
Net Margin
-6.29%
Revenue Growth (YoY)
2.26%
Profit Growth (YoY)
-14.63%
3-Year Revenue Growth
-7.18%
3-Year Profit Growth
-20.75%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
20.83
PS Ratio (TTM)
2.22
PB Ratio
2.29
Price-to-FCF
70.38
Gross Margin
33.52%
Net Margin
-6.29%
Revenue Growth (YoY)
2.26%
Profit Growth (YoY)
-14.63%
3-Year Revenue Growth
-7.18%
3-Year Profit Growth
-20.75%
4737.TW logo

4737

華廣

55.00D

1.27%

(0.01)

  • When is 4737's latest earnings report released?

    The most recent financial report for 華廣 (4737) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4737's short-term business performance and financial health. For the latest updates on 4737's earnings releases, visit this page regularly.

  • What is the operating profit of 4737?

    According to the latest financial report, 華廣 (4737) reported an Operating Profit of -62.91M with an Operating Margin of -13.72% this period, representing a growth of 0.22% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4737's revenue growth?

    In the latest financial report, 華廣 (4737) announced revenue of 458.5M, with a Year-Over-Year growth rate of -6.1%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4737 have?

    At the end of the period, 華廣 (4737) held Total Cash and Cash Equivalents of 307.28M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4737 go with three margins increasing?

    In the latest report, 華廣 (4737) did not achieve the “three margins increasing” benchmark, with a gross margin of 27.49%%, operating margin of -13.72%%, and net margin of -13.05%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4737's profit trajectory and future growth potential.

  • Is 4737's EPS continuing to grow?

    According to the past four quarterly reports, 華廣 (4737)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4737?

    華廣 (4737)'s Free Cash Flow (FCF) for the period is 32.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 110.63% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.